Vectibix Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com

Share Article

RnRMarketResearch.com adds “Vectibix (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store. This report focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market.

Vectibix Colorectal Cancer Treatment Market

Vectibix Colorectal Cancer Treatment Market

The report “Vectibix (Colorectal Cancer) – Forecast and Market Analysis to 2023” focuses on the current treatment landscape, unmet needs, current pipeline and commercial opportunities in the colorectal cancer market. Vectibix is prescribed for the treatment of advanced stage metastatic colorectal cancer. It is a monoclonal antibody and was approved by the FDA in 2006. The drug interferes with the spread of cancer in the body. The drug is administered intravenously and is typically given once in every two weeks. Side effects of vectibix include diarrhea, weakness, loss of appetite, vision changes, swelling of feet, wheezing, shortness of breath, chest pain and nausea. The drug might interact with certain other medications such as vitamins and OTC drugs. Complete Report is Available @ http://www.rnrmarketresearch.com/vectibix-colorectal-cancer-forecast-and-market-analysis-to-2023-market-report.html .

Amgen/Takeda’s EGFR antagonist Vectibix (panitumumab) was approved in the US in 2006 as a monotherapy for chemotherapy-refractory, EGFR-expressing, KRAS wild-type metastatic CRC. EU approval followed in 2007, where the agent is also indicated as a treatment for chemotherapy-refractory KRAS wild-type CRC patients, however, EGFR-expression is not specified. Additionally in the EU, the antibody is approved in combination with FOLFOX in the first-line setting, and with FOLFIRI in the second-line setting after progression on a 5-FU regimen. In April 2014, the EU label for Vectibix was updated to specify RAS wild-type disease rather than KRAS.

Reasons to Buy

  •     Understand and capitalize by identifying products that are most likely to ensure a robust return
  •     Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
  •     Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  •     Make more informed business decisions from insightful and in-depth analysis of Vectibix performance
  •     Obtain sales forecast for Vectibix from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Order a Purchase copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=251694 .

Table of Contents

1 Table of Contents
1.1 List of Tables

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Clinical Staging
3.3 Symptoms

4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Screening and Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice

5 Competitive Assessment
5.1 Overview

6 Vectibix (panitumumab)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast

7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed Colorectal Cancer Patients
7.4.2 Percent Drug-Treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Average Body Weight and Surface Area Across the 8MM
7.4.5 Individual Drug Assumptions
7.4.6 Generic Erosion
7.5 Primary Research - KOLs Interviewed for this Report
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
7.7.1 Analyst
7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Disclaimer

List of Tables
Table 1: TNM and Staging Classification System for CRC
Table 2: Symptoms of Colorectal Cancer
Table 3: Treatment Guidelines for CRC
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
Table 6: Leading Treatments for CRC, 2014
Table 7: Product Profile - Vectibix
Table 8: Vectibix SWOT Analysis, 2014
Table 9: Global Sales Forecast ($m) for Vectibix, 2013-2023
Table 10: Average Body Weight and Surface Area Across the 8MM
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Explore more reports on Cancer Drugs industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website